ZEN-3694
ZEN-3694 is a BET inhibitor from Zenith Epigenetics being tested in NUT carcinoma, where the cancer's driving fusion is itself a BET protein, and in prostate and breast cancers.
Overview
BET inhibitors block the bromodomain proteins that switch on growth genes such as MYC. NUT carcinoma is the clearest use: its BRD4-NUT fusion is a BET protein, and inhibitors make the cells differentiate in the laboratory, with objective but short-lived responses in early trials of molibresib and birabresib. ZEN-3694 is the BET inhibitor now carrying that idea forward in National Cancer Institute trials with platinum chemotherapy and with abemaciclib in NUT carcinoma, and it has been studied with enzalutamide in castration-resistant prostate cancer and with talazoparib in triple-negative breast cancer. Thrombocytopenia and fatigue are the class side effects.
Binds the bromodomains of BRD2, BRD3 and BRD4 so they cannot read acetylated histones; in NUT carcinoma this displaces the BRD4-NUT fusion from chromatin and lets the cells differentiate, and in other cancers it lowers MYC and androgen receptor signalling.
1.ZEN-3694 slips into a pocket on its target.
- AmivantamabApproved
- CamizestrantApproved
- Comprehensive genomic profilingStandard of care
- Liquid biopsy (ctDNA)Standard of care
- LorlatinibApproved
- MRD / molecular residual disease testingEstablished
- ADC payload neutralisersPhase 1
- BGB-16673Phase 3
- Bispecific ADCPhase 3
- BRUIN CLL-321Positive
- CaDAnCe-304Recruiting
- CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)Active
- A clone report from blood at every treatment cycle
- A fast route to the matched drug when it is licensed for another cancer
- A multi-cancer platform trial of adaptive (dose-holiday) therapy
- A national rapid research autopsy network for end-stage cancer
- A standard evolvability score for every tumour
- A standing platform trial that assigns treatment by how the tumour escaped
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas · Lines of therapy.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"ZEN-3694" OR ABSTRACT:"ZEN-3694" OR TITLE:"ZEN003694" OR ABSTRACT:"ZEN003694" OR TITLE:"Zenith BET inhibitor" OR ABSTRACT:"Zenith BET inhibitor") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ZEN-3694, not a curated reading list.
Similar pages
not linked directly; found by shared links- TrialCemiplimab in metastatic or unresectable NUT carcinoma (Northwestern pilot)
Shares NUT carcinoma (midline carcinoma with NUTM1 rearrangement) and the tag owner-request.
- TrialTazemetostat with doxorubicin as front-line therapy for advanced epithelioid sarcoma (EZH-301 run-in)
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET) and the tag owner-request.
- TrialSABR-COMET: stereotactic ablative radiotherapy for oligometastatic cancer
Shares Prostate cancer and the tag owner-request.
- PersonWilliam G. Nelson
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Prostate cancer.
- CompanyProxygen
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Prostate cancer.
- IdeaEradicate dormant cancer cells: a programme to wake and kill or lock asleep disseminated cells
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Prostate cancer.
- CompanyFoghorn Therapeutics
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Prostate cancer.
- CompanyK36 Therapeutics
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Prostate cancer.